The USPTO published patent application US20260090993A1, filed by Mirum Pharmaceuticals, Inc. and inventor Parag VED, covering pharmaceutical compositions comprising maralixibat or a pharmaceutically acceptable salt. The application claims solid dosage drug products and methods of using these compositions for treating cholestatic pruritus and cholestatic liver disease. The patent contains 8 CPC classifications covering drug formulations (A61K 9/2009 series), the active compound (A61K 31/4995), and various excipients (A61K 47/10, 47/12, 47/183, 47/22).

This patent publication is informational and does not impose compliance requirements on third parties. Pharmaceutical companies developing maralixibat formulations or competing products should review the claimed compositions and uses to assess potential freedom-to-operate considerations. No immediate action is required; the application represents potential future IP claims that may affect product development strategies.